Finch Therapeutics Group, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Collaboration Revenue
Royalty Revenue From Related Party
Total revenue
OPERATING EXPENSES:
Research and development
General and administrative
Impairment of in-process research and development
Impairment of long-lived assets
Restructuring
Total operating expenses
Net loss from operations
OTHER INCOME, NET:
Gain on extinguishment of PPP Loan
Interest income, net
Gain on lease termination
Loss on loan extinguishment
Gain (loss) on sale and disposal of fixed assets, net
Sublease and other income
Total other income, net
Loss before income taxes
Income tax benefit
Net loss
Net loss per share attributable to common stockholders—basic and diluted
Weighted-average common stock outstanding—basic and diluted
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted
Weighted-average common stock outstanding, basic
Weighted-average common stock outstanding, diluted

Comments